

Baricade-Delay T1D at-risk study

Principal Investigator: Dr. Tom Elliott **SubInvestigator:** Dr. Dale Clayton

Study coordinator & primary contact Marla Inducil MD, Hector Com MD, Glaliza Erfe MD P:
604-628-7253 x 7011, minducil@bcdiabetes.ca

Summary: **Baricade-Delay** is a Phase 3, Double-Blind, Randomized, Placebo-Controlled study of baricitinib to delay onset and diagnosis of Stage 3 Type 1 Diabetes in at-risk participants (Stage 1b or Stage 2) aged ≥ 1 to < 36 years

Study location: [BCDiabetes: 400 - 210 West Broadway, Vancouver V5Y 3W2](#)

Background & hypothesis: Type 1 diabetes (T1D) is characterized by autoimmune destruction of the insulin producing pancreatic β cells. Screening and identification of islet autoantibody positive individuals has resulted in the recognition that T1D is a continuum of stages with genetic risk and autoimmunity (Stages 1 and 2) preceding the development of Stage 3 T1D (fully-blown T1D). The goal of an effective therapeutic for the delay of Stage 3 T1D is intervention to preserve β cell function. **Baricitinib** is a JAK inhibitor that has immunomodulatory and anti-inflammatory effects. Direct and indirect evidence showed that baricitinib can preserve β cell function by blocking the JAK pathway which is involved in T1D pathogenesis. Click [here](#) to learn about Tzield, a Health Canada approved treatment for stage 2 T1D

Eligible Participants include:

- individuals aged ≥ 1 to < 36 years of age
- at least one documented occasion of at least 2 diabetes-related autoantibodies
- Meet definition for Stage 2 T1D dysglycemia or Stage 1b T1D
- any one of: A1C 5.7-6.4%; Fasting BG 6.1 - 6.9; 2 hr BG 7.8 - 11.1 or 10% rise in A1c
- body weight ≥ 8 kg; BMI < 35

Treatment course and duration: This study consists of an optional prescreening period (at least 12 weeks before screening), 4-week screening period (V1-V2), a 117-week treatment period (V3-V14) where participants will take 4mg or 2mg of baricitinib or placebo orally daily, and a 4-week safety follow-up period. Participants will continue with the treatment until the diagnosis of Stage 3 T1D is established. Those who do not develop Stage 3 T1D after week 117 will have continuation visits (CV) every 26 weeks and continuation visit-telehealth (CV-T) every 13 weeks after CV, until the last visit criteria is met.

	Pre-screening	Screening		Treatment Period *												Safety Follow-Up (4 weeks)
				Baricitinib												
				Placebo												
Visit Number	601	1	2	3	4	5	6	7	8	9		14	CV	CV-T Visits	Final Visit	801
Weeks from Randomization	-16 to -4	-4 to 0		0	2	6	12	24	36	52	117				

↑
Randomization 2:1

Odds of receiving placebo: 33% (one third)

Study documents:

Informed Consent

[Conflict of Interest statement](#)

Short URL = <https://bit.ly/baricadeT1>